论文部分内容阅读
目的:评价前列地尔与酚妥拉明和氯沙坦用于治疗肺心病患者伴肺动脉高压症的临床疗效。方法:选取2015年4月—2016年2月收治的肺心病伴肺动脉高压症患者42例临床资料,将其随机分为治疗组22例与对照组20例;对照组患者在常规治疗基础上均给予前列地尔及酚妥拉明治疗,治疗组患者在对照组基础上加用氯沙坦治疗,比较两组患者连续治疗14 d后肺动脉压的降压效果和总有效率。结果:治疗组患者治疗后的肺动脉压下降幅度优于对照组(P<0.05),治疗后的总有效率为95.45%高于对照组为65.00%(χ~2=6.301,P<0.05)。结论:采用前列地尔与酚妥拉明和氯沙坦治疗肺心病伴肺动脉高压患者,可有效降低患者肺动脉压。
PURPOSE: To evaluate the clinical efficacy of alprostadil and phentolamine and losartan in the treatment of patients with pulmonary heart disease and pulmonary hypertension. Methods: Forty-two patients with pulmonary heart disease and pulmonary hypertension admitted from April 2015 to February 2016 were selected and randomly divided into treatment group (n = 22) and control group (n = 20). Patients in the control group were treated on the basis of routine treatment Patients were given prostaglandin and phentolamine. Patients in the treatment group were treated with losartan on the basis of the control group. The antihypertensive effect and total effective rate of pulmonary arterial pressure were compared between the two groups after 14 days of continuous treatment. Results: The decrease of pulmonary arterial pressure in the treatment group was better than that in the control group (P <0.05). The total effective rate was 95.45% in the treatment group and 65.00% in the control group (χ ~ 2 = 6.301, P <0.05). Conclusions: The use of alprostadil and phentolamine and losartan in patients with pulmonary heart disease and pulmonary hypertension can reduce pulmonary hypertension.